A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy

A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy

Uterine leiomyosarcomas (ULMS) are a rare cause of uterine malignancy. Due to their aggressive nature, resistance to standard therapy and high rates of recurrence, they are associated with a very poor prognosis, irrespective of their stage at diagnosis. A 68-year-old female, Chinese patient was diag...

Full description

Bibliographic Details
Main Authors: Rebecca Lin, Asyraf Muaadz, Ho Gwo Fuang
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Gynecologic Oncology Reports
Subjects:
Refractory uterine leiomyosarcoma
Combination therapy
Pembrolizumab
Temzolomide
Uterine malignancy
Immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578924000055

Internet

http://www.sciencedirect.com/science/article/pii/S2352578924000055

Similar Items